FDA Approves Yorvipath for Hypoparathyroidism

433 Views

Emedinexus 08 January 2025

The U.S. Food and Drug Administration (FDA) has granted approval for Yorvipath (palopegteriparatide) for subcutaneous use in adults with hypoparathyroidism. This treatment targets the insufficient production of parathyroid hormone, a condition that can lead to low calcium levels.

To comment on this article,
create a free account.

Already registered?

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.